Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?
Isabelle Delattre(Cliniques Universitaires Saint-Luc), Paul M. Tulkens(UCLouvain), Thierry Dugernier(Clinique Saint Pierre), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Maya Hites(Université Libre de Bruxelles), Françoise Van Bambeke(Institut de Pharmacologie Moléculaire et Cellulaire), Herbert Spapen(Universitair Ziekenhuis Brussel), Fabio Taccone(Erasmus Hospital), Pierre Wallemacq(Cliniques Universitaires Saint-Luc), Frédérique Jacobs(Université Libre de Bruxelles)
Cited by 103
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k
Tackling antibiotic resistance
|Nature Reviews Microbiology|2011|1.1k
Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
|JAMA|2003|958
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890